Maggie Cheang
Maggie Cheang
Dirección de correo verificada de
Citado por
Citado por
Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study
LA Carey, CM Perou, CA Livasy, LG Dressler, D Cowan, K Conway, ...
Jama 295 (21), 2492-2502, 2006
Supervised risk predictor of breast cancer based on intrinsic subtypes
JS Parker, M Mullins, MCU Cheang, S Leung, D Voduc, T Vickery, ...
Journal of clinical oncology 27 (8), 1160, 2009
Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma
TO Nielsen, FD Hsu, K Jensen, M Cheang, G Karaca, Z Hu, ...
Clinical cancer research 10 (16), 5367-5374, 2004
Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer
MCU Cheang, SK Chia, D Voduc, D Gao, S Leung, J Snider, M Watson, ...
JNCI: Journal of the National Cancer Institute 101 (10), 736-750, 2009
Metastatic behavior of breast cancer subtypes
H Kennecke, R Yerushalmi, R Woods, MCU Cheang, D Voduc, ...
Journal of clinical oncology 28 (20), 3271-3277, 2010
Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype
MCU Cheang, D Voduc, C Bajdik, S Leung, S McKinney, SK Chia, ...
Clinical cancer research 14 (5), 1368-1376, 2008
Breast cancer subtypes and the risk of local and regional relapse
KD Voduc, MCU Cheang, S Tyldesley, K Gelmon, TO Nielsen, ...
Journal of clinical oncology 28 (10), 1684-1691, 2010
Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 …
FM Blows, KE Driver, MK Schmidt, A Broeks, FE Van Leeuwen, ...
PLoS medicine 7 (5), e1000279, 2010
Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer
I Garcia-Murillas, G Schiavon, B Weigelt, C Ng, S Hrebien, RJ Cutts, ...
Science translational medicine 7 (302), 302ra133-302ra133, 2015
A Comparison of PAM50 Intrinsic Subtyping with Immunohistochemistry and Clinical Prognostic Factors in Tamoxifen-Treated Estrogen Receptor–Positive Breast CancerPAM50 in ER …
TO Nielsen, JS Parker, S Leung, D Voduc, M Ebbert, T Vickery, SR Davies, ...
Clinical cancer research 16 (21), 5222-5232, 2010
Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial
J Hugh, J Hanson, MCU Cheang, TO Nielsen, CM Perou, C Dumontet, ...
Journal of clinical oncology 27 (8), 1168, 2009
Prognostic significance of progesterone receptor–positive tumor cells within immunohistochemically defined luminal A breast cancer
A Prat, MCU Cheang, M Martín, JS Parker, E Carrasco, R Caballero, ...
Journal of clinical oncology 31 (2), 203, 2013
Molecular characterization of basal‐like and non‐basal‐like triple‐negative breast cancer
A Prat, B Adamo, MCU Cheang, CK Anders, LA Carey, CM Perou
The oncologist 18 (2), 123-133, 2013
Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial
A Tutt, H Tovey, MCU Cheang, S Kernaghan, L Kilburn, P Gazinska, ...
Nature medicine 24 (5), 628-637, 2018
Use of immunohistochemical markers can refine prognosis in triple negative breast cancer
M Tischkowitz, JS Brunet, LR Bégin, DG Huntsman, MCU Cheang, ...
BMC cancer 7 (1), 1-11, 2007
Human epidermal growth factor receptor 2 overexpression as a prognostic factor in a large tissue microarray series of node-negative breast cancers
S Chia, B Norris, C Speers, M Cheang, B Gilks, AM Gown, D Huntsman, ...
Journal of Clinical Oncology 26 (35), 5697-5704, 2008
Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657)
LJ Esserman, DA Berry, MCU Cheang, C Yau, CM Perou, L Carey, ...
Breast cancer research and treatment 132 (3), 1049-1062, 2012
Akt phosphorylates the Y-box binding protein 1 at Ser102 located in the cold shock domain and affects the anchorage-independent growth of breast cancer cells
BW Sutherland, J Kucab, J Wu, C Lee, MCU Cheang, E Yorida, D Turbin, ...
Oncogene 24 (26), 4281-4292, 2005
Molecular heterogeneity and response to neoadjuvant human epidermal growth factor receptor 2 targeting in CALGB 40601, a randomized phase III trial of paclitaxel plus …
LA Carey, DA Berry, CT Cirrincione, WT Barry, BN Pitcher, LN Harris, ...
Journal of Clinical Oncology 34 (6), 542, 2016
Use of mutation profiles to refine the classification of endometrial carcinomas
MK McConechy, J Ding, MCU Cheang, KC Wiegand, J Senz, AA Tone, ...
The Journal of pathology 228 (1), 20-30, 2012
El sistema no puede realizar la operación en estos momentos. Inténtalo de nuevo más tarde.
Artículos 1–20